Acceptability and use of a dapivirine vaginal ring in a phase III trialElizabeth Montgomery, Jared M. Baeten, Teopista Nakyanzi et al.|AIDS|2017Cited by 137
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trialGonasagrie Nair, Kenneth Ngure, Connie Celum et al.|The Lancet HIV|2023Cited by 62
Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention TrialElizabeth Montgomery, Sarah T. Roberts, Gonasagrie Nair et al.|AIDS and Behavior|2019Cited by 47
Favoring “Peace of Mind”: A Qualitative Study of African Women's HIV Prevention Product Formulation Preferences from the MTN-020/ASPIRE TrialAriane van der Straten, Felix Mhlanga, Mary Kate Shapley‐Quinn et al.|AIDS Patient Care and STDs|2017Cited by 46
Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III TrialThesla Palanee‐Phillips, Sarah T. Roberts, Krishnaveni Reddy et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2018Cited by 44